Prof M. John Chapman BSc (Hons), PhD, DSc

John Chapman is the Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris, France, affiliated to the Medical Faculty of the Pierre and Marie Curie University, Paris. In 2002, he was appointed to a Senior Clinical Investigatorship in the Paris Hospitals – Public Assistance Healthcare System, and was nominated as a Distinguished Fellow of the International Atherosclerosis Society in 2007.

John Chapman is a longstanding member of the European Atherosclerosis Society and is President-Elect for the period 2008-2009. He is also a member of the Executive Committee of the International Atherosclerosis Society, a Past-President of the French Atherosclerosis Society (FSA;1997- 2003), and in 2003 was elected President of the newly created “Nouvelle Societe Francaise de l’Atherosclerose” (NSFA; 2003 to 2006).

The focal points of his research interests have been (i) the structure, metabolism, and biological activities of atherogenic apolipoprotein B-containing particle subspecies (VLDL, LDL and Lp(a)), (ii) the relationship of HDL particle heterogeneity to atheroprotective activity in normolipidemia and in atherogenic dyslipidemia, (iii) the role of CETP in the regulation of intravascular lipoprotein metabolism, (iv) the pharmacological modulation of lipoprotein metabolism in atherogenic dyslipidemias and metabolic disease, and (v) the role of monocyte-macrophages and foam cells in the inflammatory fragilisation and thrombogenicity of the atherosclerotic plaque. In recognition of his contributions to the field of Plasma lipoproteins: Structure, Metabolism and Role in Atherothrombosis he was awarded the Doctor of Science degree by the University of London in 2002.

Professor Chapman is presently Associate European Editor of Arteriosclerosis, Thrombosis and Vascular Biology and Pharmacology and Therapeutics. He is an Editorial Board member of Atherosclerosis, Future Lipidology and Current Medical Research and Opinion. He has authored more than 380 peer-reviewed publications and book chapters, including articles in Nature, Nature Cardiovascular Medicine, Pharmacological Reviews, PNAS, Circulation and FASEB J.

John Chapman received his B.Sc. (Hons) degree at the University of Aberdeen, Scotland, and his Ph.D. degree in Medical Biochemistry at the Middlesex Hospital Medical School, University of London. His postdoctoral training in Cardiovascular Lipidology was completed at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, under the direction of Dr R.J. Havel. He served as an Established Research Investigator at INSERM from 1978 to 1982, and trained in Biophysics with Dr D.M. Small at Boston University and in Cell Receptor Biology with Profs. Brown and Goldstein at Southwestern Medical School in Dallas. John Chapman was an Honorary Visiting Research Scientist at the Gladstone Foundation for Cardiovascular Disease in San Francisco(1982-1985) where he studied the receptor-binding domains of apo B100.


Most recent publications:

Out R, Jessup W, Le Goff W, Hoekstra M, Gelissen IC, Zhao Y, Kritharides L, Chimini G, Kuiper J, Chapman MJ, Huby T, Van Berkel TJC, Van Eck M. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 2007 Oct 25;
www.ncbi.nlm.nih.gov/sites/entrez

Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, Thuren T, Shear CL, Chapman MJ. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 2007 Oct 19;
www.ncbi.nlm.nih.gov/sites/entrez


Most cited publications:

Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111:983-908.
www.ncbi.nlm.nih.gov/sites/entrez

Barter PJ, Brewer HB Jr , Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7
www.ncbi.nlm.nih.gov/sites/entrez

Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:1881-8.
www.ncbi.nlm.nih.gov/sites/entrez

Le Goff W, Guerin M, Chapman MJ, Thillet J. A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression. J Lipid Res 2003;44:902-10.
www.ncbi.nlm.nih.gov/sites/entrez

Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003;88:3738-46.
www.ncbi.nlm.nih.gov/sites/entrez